GPT and metabolic dysfunction-associated steatotic liver disease: In another study on patients with T2DM and NAFLD, younger age was associated with a greater reduction in ALT levels with dapagliflozin treatment, but it was not statistically significant (OR = 0.954, P = 0.147) (27).